Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702636 | 0.85 | CYP3A4 (0.48) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL30628861 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL29119428 | 0.83 | MAP2K2 (0.36) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| Nitrogen SCHEMBL27862489 | 0.83 | CYP3A4 (0.47) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL164718 | 0.83 | TSHR (0.48) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL29555850 | 0.83 | TSHR (0.48) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL619229 | 0.83 | ALDH1A1 (0.36) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL1143074 | 0.83 | CD44 (0.50) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL1622559 | 0.83 | ALOX15 (0.48) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL31208138 | 0.83 | CD44 (0.50) | ALDH1A1CYP3A4TSHRHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574368-A | High-dielectric low-loss intrinsic polyimide film and preparation method and application thereof | 大同共聚(西安)科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-104927072-B | A kind of Kapton and preparation method thereof of solvent resistant low thermal coefficient of expansion | 六安市杜尔邦绝缘材料有限公司 | 2019-05-14 | — | — | CN | claimed |
| CN-104927072-A | Solvent-resistant polyimide thin film with low thermal expansion coefficient and preparation method for polyimide thin film | LU AN CITY DUERBANG INSULATION MATERIALS CO LTD | 2015-09-23 | — | — | CN | claimed |
| EP-4263518-B1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12570615-B2 | Quinazolinone derivatives | HOFFMANN-LA ROCHE INC. | 2026-03-10 | — | — | US | disclosed |
| CN-121574368-A | High-dielectric low-loss intrinsic polyimide film and preparation method and application thereof | 大同共聚(西安)科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4073044-B1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | HOFFMANN LA ROCHE (CH) | 2025-02-19 | — | — | EP | disclosed |
| CN-114746405-B | Novel BRAF inhibitors as anomalous breakers | 豪夫迈·罗氏有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4263518-A1 | NEW QUINAZOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116601147-A | Novel quinazolinone derivatives | 豪夫迈·罗氏有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2006081072-A1 | ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0382216-B1 | Novel substituted acetamide compounds | TOYO BOSEKI (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-5041462-A | Novel substituted acetamide compounds and use as anti-allergic agents | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0382216-A1 | Novel substituted acetamide compounds | Toyo Boseki Kabushiki Kaisha (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4504660-A | Process for the production of 2,6-diaminobenzonitrile derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-03-12 | — | — | US | disclosed |
| US-4504660-A | Process for the production of 2,6-diaminobenzonitrile derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-03-12 | — | — | US | disclosed |
| US-4504660-A | Process for the production of 2,6-diaminobenzonitrile derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-03-12 | — | — | US | disclosed |
| US-4126617-A | PROPHYLAXIS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-3959289-A | PROPHYLACTICS IN ALLERGIES | THE UPJOHN COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | NDUFS3, NQO2, NDUFC1 | ALDH1A1 307/4885CYP3A4 64/4885TSHR 1618/4885 |
| US-12570615-B2 | Quinazolinone derivatives | ABL1, NQO2, CNR1 | ALDH1A1 321/4885CYP3A4 129/4885TSHR 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.